Abstract
Efficacy of adalimumab in nail psoriasis by baseline subgroups, and overall safety from first 26 weeks of a phase 3, randomized, placebo-controlled trial
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
